Skip to main content
. Author manuscript; available in PMC: 2019 Nov 18.
Published in final edited form as: J Diabetes Mellitus. 2016 Nov 17;6(4):277–290. doi: 10.4236/jdm.2016.64029

Figure 4.

Figure 4.

12LO deficient NOD mice treated with Ad-ANGPTL8 or Ad-GFP. (a) The expression of ANGPTL8 was determined by qPCR in the liver of Ad-ANGPTL8 (ANGPTL8) or Ad-GFP (GFP) treated 12LO deficient (12LOKO) NOD mice. Beta actin was used as an internal control; (b) Serum triglycerides at the time of harvest. GTT (c) and ITT (d) comparing 12LOKO NOD mice that received Ad-ANGPTL8 or Ad-GFP. Blood glucose (e) and serum insulin (f) after 4 hour fasting 13 days post adenovirus administration. BW (g) at the time of harvest. Beta cell area (h), BrdU positive beta cells (i), and representative image (j) compared between ANGPTL8 and GFP groups in 12LOKO NOD mice. Data are means ± SEM; n = 5 – 6 per group. *: p < 0.05.